Boehringer Ingelheim marks great progress in immuno-oncology research partnerships in 2017
- Details
- Category: Boehringer Ingelheim
2017 marks a year of significant advancement for Boehringer Ingelheim as it secured a range of external partnerships with the goal of transforming the lives of patients and winning the fight against cancer. External partnerships complement Boehringer Ingelheim's two-pronged research strategy - investigating both cancer cell-directed therapies and immune cell-directed therapies.
Novartis tender offer for Advanced Accelerator Applications commences
- Details
- Category: Novartis
Novartis AG (NYSE: NVS) ("Novartis") today announced that its direct and indirect subsidiary, Novartis Groupe France S.A., a société anonyme organized under the laws of France ("Purchaser"), has commenced a cash tender offer to purchase all of the outstanding ordinary shares, nominal value EUR 0.10 per share, including Ordinary Shares represented by American Depositary Shares (ADS), of Advanced Accelerator Applications (NASDAQ: AAAP) ("AAA"), for a price of USD 41.00 per Ordinary Share and USD 82.00 per ADS, in each case, payable net to the seller thereof in cash, without interest, less any withholding taxes that may be applicable (the "Offer").
Sanofi explores combination treatments for multiple myeloma in new late-stage trials
- Details
- Category: Sanofi
Sanofi has launched two new late-stage clinical studies to determine if an investigational biologic called isatuximab, when used in combination with other commonly used cancer treatments, might be an effective treatment option for certain people with multiple myeloma, a rare blood cancer related to lymphoma and leukemia.
Interim results of first-ever global survey show people with type 2 diabetes underestimate their cardiovascular risk
- Details
- Category: Novo Nordisk
Today the International Diabetes Federation (IDF) presented the interim results of the first ever multi-country online survey on CVD risk awareness and knowledge among people living with type 2 diabetes, indicating low levels of awareness and limited dialogue between patients and healthcare professionals. The global survey - Taking Diabetes to Heart - developed in partnership with Novo Nordisk, runs until March 2018 and is open to all people with type 2 diabetes.
Bristol-Myers Squibb and Pfizer Alliance urge people to 'Tune in to AFib, Take Note of Stroke Risk'
- Details
- Category: Bristol-Myers Squibb
The Bristol-Myers Squibb and Pfizer Alliance, the National Stroke Association and iHeartMedia today launched 'Tune in to AFib, Take Note of Stroke Risk' to educate the estimated nearly seven million Americans in 2017 living with atrial fibrillation (AFib) not caused by a heart valve problem about their increased risk of stroke.
Pfizer enters into agreement to develop and commercialize CRESEMBA® (isavuconazole) in China and Asia Pacific region
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) and Basilea Pharmaceutica Ltd. (SIX:BSLN), an international biopharmaceutical company specializing in the research and development of anti-infective and oncological medicines, today announced they have entered into an agreement whereby Pfizer will be granted the exclusive development and commercialization rights in China and several countries in the Asia Pacific region to CRESEMBA (isavuconazole).
Novartis announces Phase III STRIVE data published in NEJM demonstrating significant and sustained efficacy of erenumab (AMG334) in migraine prevention
- Details
- Category: Novartis
Novartis today announced that the New England Journal of Medicine (NEJM) published positive results from the six-month Phase III STRIVE study evaluating erenumab in the prevention of episodic migraine (defined in STRIVE as 4 to 14 migraine days per month)[1]. Erenumab delivered clinically meaningful and statistically significant differences from placebo for all primary and secondary endpoints including those measured by the novel, validated Migraine Physical Function Impact Diary (MPFID)[2].
More Pharma News ...
- Bristol-Myers Squibb awards "Golden Tickets" for LabCentral to Neutrolis, Remora Therapeutics
- AstraZeneca and Chinese Future Industry Investment Fund establish joint venture to develop new medicines in China
- Novartis' Ultibro® Breezhaler® significantly improved COPD patients' lung function after direct switch from Seretide®
- GSK submits landmark IMPACT data to US regulatory authority to support expanded label for Trelegy Ellipta
- Boehringer Ingelheim makes many of its best molecules openly available to the scientific community via opnMe.com to unlock their full potential
- Roche to acquire Viewics, Inc. to provide data-driven lab business analytics and add further digital capabilities along the laboratory value chain
- Novartis, ASCP and ACS join forces to fight cancer in Ethiopia, Uganda and Tanzania